Sanofi to shut off Genzyme's Cambridge R&D site
Cambridge - Genzyme will shut the doors at its Cambridge R&D site by the end of the year, with up to 60 employees expected to lose their jobs. The move is part of an ongoing global restructuring of R&D by Sanofi, who purchased Genzyme for US-$20b last year. Sanofi announced that it would close the Milton Road site in Cambridge by the end of 2012, whereas the plants in Haverhill and the base in Oxford would remain. It is another blow to Britain’s R&D landscape after Pfizer announced the closure of its research site in Sandwich last year. Sanofi announced the start of a consultation in November to consolidate all of its R&D centres into four global hubs, which includes Genzyme’s research sites. This will affect R&D sites in the US, Germany, France and Asia, which could lead to further job losses in these regions. No final decision has been made as this consultation is just starting, Sanofi said, adding that it would communicate plans for the European R&D hubs following the consultation with its social partners. Sanofi said it “remains committed to keeping its strategic presence in the UK,” and that Genzyme would continue to invest in clinical trials in the country, and has already invested £17.8m (€21m)in trials over the past four years. According to Sanofi, the company is planning to consolidate its research operations to European centres in Germany, France, Asia, aside from its Boston Genzyme R&D wing.